Each tablet contains 80 mg of Artemether and 480 mg of Lumefantrine, along with excipients and coloring agents.
Treatment of malaria, including multi-drug resistant strains of P. falciparum.
Six tablets total for individuals 35 kg and above: one tablet at 0, 8, 24, 36, 48, and 60 hours. Take with food, especially a fatty meal.
No specific negative drug-drug interactions observed. Avoid grapefruit juice. Caution with drugs that prolong the QT interval.
Rash, trouble sleeping, nausea, vomiting, diarrhea, and coughing. Seek medical attention if these persist.
Hypersensitivity to Artemether or Lumefantrine. Caution in patients taking drugs that prolong the QT interval.
Avoid during pregnancy unless essential. Do not use during breastfeeding and for at least one week after stopping treatment.
Artemether generates cytotoxic oxygen and free radicals. Lumefantrine interferes with polymerization. Both diminish nucleic acid and protein synthesis.
Artemether: rapidly absorbed, metabolized to DHA, half-life of 2-4 hours. Lumefantrine: absorption enhanced by fatty foods, metabolized to a more potent form, half-life of 4-6 days.
A new complete three-day treatment course is recommended.